Drug interactions
Pazopanib + Topiramate
Severity: Minor
Pazopanib and Topiramate: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pazopanib is a CYP3A4 substrate, and enzyme induction may reduce its exposure and antitumour effect. Topiramate is a weak inducer, so clinically important changes are uncertain.
What this interaction means in plain words
Pazopanib and Topiramate have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Pazopanib belongs to Oncology; Topiramate belongs to Central Nervous System.
Why it happens
Weak CYP3A4 induction by topiramate may increase pazopanib metabolism.
What to do
No routine dose change is needed; monitor tumour response and tolerability and reassess if efficacy declines.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Pazopanib and Topiramate, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Topiramate
Other interactions of Pazopanib
- Adagrasib + Pazopanib Major
- Amiodarone + Pazopanib Major
- Amisulpride + Pazopanib Major
- Amobarbital + Pazopanib Major
- Anagrelide + Pazopanib Major
- Apalutamide + Pazopanib Major
Frequently asked questions
Can I take Pazopanib with Topiramate?
MediHelp rates the interaction as minor. Pazopanib and Topiramate have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Pazopanib is a CYP3A4 substrate, and enzyme induction may reduce its exposure and antitumour effect. Topiramate is a weak inducer, so clinically important changes are uncertain.
How serious is the interaction between Pazopanib and Topiramate?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine dose change is needed; monitor tumour response and tolerability and reassess if efficacy declines.
What other medicines interact with Topiramate?
MediHelp also lists interactions of Topiramate with, for example, Benzhydrocodone / acetaminophen, Buprenorphine long-acting, Buprenorphine subdermal implant. The full list is on the Topiramate page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
